Abstract：Objective To analyze the clinical prognosis of patients with cervical and upper thoracic esophageal squamous cell carcinoma treated with radical intensity-modulated radiotherapy (IMRT) with or without chemotherapy, and to explore the significance of elective lymph node irradiation (ENI). Methods A retrospective analysis was performed on 309 patients with cervical and upper thoracic esophageal squamous cell carcinoma who underwent IMRT with or without chemotherapy in the Department of Radiology, the Fourth Hospital of Hebei Medical University. The prognostic factors were analyzed and patients receiving different irradiation methods were assigned into different group. The curative effect, toxicity and side effects were analyzed among different groups. Results The 1-, 3-and 5-year overall survival (OS) and progression-free survival (PFS) were 76.7%, 37.4%, 19.3% and 59.7%, 27.4% and 14.4%, respectively, with median values of 26.8 and 15.5 months. Multivariate analysis showed that gender, cTNM staging and chemotherapy were the prognostic factors affecting the OS (P=0.003, P<0.001, P=0.022), and gender, cTNM stage and radiation mode were the prognostic factors affecting the PFS (P=0.016, P<0.001, P=0.008). After propensity score matching (PSM), the 1-, 3-, and 5-year OS and PFS were 77.2%, 39.3%, 20.0%, and 62.0%, 29.3%, and 15.4%, respectively, with median values of 27.1 and 18.2 months. Multivariate analysis showed that gender, cTNM staging and chemotherapy were the prognostic factors affecting the OS (P=0.026, P<0.001, P=0.017);cTNM staging and irradiation mode were the prognostic factors affecting the PFS (P<0.001, P=0.008). A subgroup analysis of chemotherapy showed that patients receiving 3-4 cycles of chemotherapy were preferred. The side effects of the patients were mainly grade 0 to 2, which could be tolerated. Conclusions IMRT combined with or without chemotherapy is an efficacious treatment for patients with cervical and upper thoracic esophageal squamous cell carcinoma;ENI can improve the PFS of patients.
Shen Wenbin,Xu Jinrui,Li Shuguan et al. Prognostic analysis of intensity-modulated radiotherapy for cervical and upper thoracic esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 842-848.
[1] Smith TJ, Ryan LM, Douglass HO, et al. Combined chemotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus:a study of the Eastern Cooperative Oncology Group[J]. Int J Radiat Oncol Biol Phay, 1998, 42(2):269-284. DOI:10.1016/s0360-3016(98)00232-6. [2] Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma:role of surgery and other modalities[J]. Lancet Oncol, 2007, 8(6):545-553. DOI:10.1016/S1470-2045(07)70172-9. [3] International Agency for Research on Cancer. Cancer incidence, mortality and prevalence worldwide in 2008[DB/OL].[2019-03-01][2020-05-20].http://dobocaJl.iarc.fr/. [4] Ajani JA, D′Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers,version 1.2015[J]. J Natl Compr Cane Netw, 2015, 13(2):194-227. DOI:10.6004/jnccn.2015.0028. [5] Wang W, Li J, Zhang Y, et al. Comparison of patient-specific internal gross tumor volume for radiation treatment of primary esophageal cancer based separately on three-dimensional and four-dimensional computed tomography images[J]. Dis Esophagus, 2013, 27(4):348-354. DOI:10.1111/dote.12089. [6] 白文文, 周志国, 宋玉芝, 等. 颈段食管癌三维适形与调强放疗的剂量学及临床对比研究[J]. 中华放射医学与防护杂志, 2014, 34(12):919-921. DOI:10.3760/cma.j.issn.0254.5098.2014.12.010. Bai WW, Zhou ZG, Song YZ, et al. Dosimetry and clinical comparative study of three dimensional conformal and intensity modulated radiotherapy for cervical esophageal cancer[J]. Chin J Radiol Med Prot, 2014, 34(12):919-921. DOI:10.3760/cma.j.issn.0254.5098.2014.12.010. [7] 刘粉霞, 翟倩倩, 孙晓东, 等. 胸上段食管癌3D-CRT与IMRT的剂量学比较[J]. 实用肿瘤学杂志, 2014, 28(1):34-38. DOI:10.3969/j.issn.1002-3070.2014.01.1007. Liu FX, Zhai QQ, Sun XD, et al. Dosimetric comparison between intensity -modulated radiotherapy and conformal radiotherapy for upper thoracic esophageal carcinoma[J]. J Pract Oncol, 2014, 28(1):34-38. DOI:10.3969/j.issn.1002-3070.2014.01.1007. [8] 沈文斌, 高红梅, 祝淑钗, 等. 选择性区域淋巴结照射对临床早期食管癌放疗疗效的影响[J]. 中华放射医学与防护杂志, 2015, 35(4):265-269. DOI:10.3760/cma.j.issn.0254-5098.2015.04.007. Shen WB, Gao HM, Zhu SC, et al. Analysis on efficacy of different radiotherapy methods in no-metastasis esophageal squamous cell carcinoma[J]. Chin J Radiol Med Prot, 2015, 35(4):265-269. DOI:10.3760/cma.j.issn.0254-5098.2015.04.007. [9] 祝淑钗, 尤鑫, 李曙光, 等. 食管癌三维适形调强放疗不同靶区照射局部失败的剂量学比较[J]. 中华放射医学与防护杂志, 2015, 35(11):830-834. DOI:10.3760/ema.j.issn.0254-5098.2015.11.007. Zhu SC, You X, Li SG, et al. Comparison of dose-volume parameters for local failure in esophageal cancers treated by 3D-CRT or IMRT with different target regions[J]. Chin J Radiol Med Prot, 2015, 35(11):830-834. DOI:10.3760/ema.j.issn.0254-5098.2015.11.007. [10] Lagergren P, Avery KNL, Hughes R, et al. Health-related quality of life among patients cured by surgery for esophageal cancer[J]. Cancer, 2007, 110(3):686-693. DOI:10.1002/cncr.22833. [11] Blazeby JM, Farndon JR, Donovan J, et al. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma[J]. Cancer, 2000, 88(8):1781-1787. DOI:10.1002/(sici)1097-0142(20000415)88:8<1781::aid-cncr4>3.0.co;2-g. [12] Chen F, Li J, Ai N, et al. Influence of 3D-CRT and conformal IMRT on thyroid function of patients with cervical and upper thoracic esophageal cancer and comparison of clinical efficacy[J]. Oncol Lett, 2019, 17(3):3432-3438. DOI:10.3892/ol.2019.9989. [13] Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1):94-102. DOI:10.1016/j.ijrobp.2006.12.031. [14] Chan A, Wong A, Turrisi A, et al. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2):265-270. DOI:10.1016/s0360-3016(99)00199-6. [15] Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T2-3 Nany M0 squamous cell carcinoma of the esophagus[J]. Int J Radiat Oncol, 2003, 57(2):425-433. DOI:10.1016/s0360-3016(03)00585-6. [16] Valmasoni M, Pierobon ES, Zanchettin G, et al. Cervical esophageal cancer treatment strategies:a cohort study appraising the debated role of surgery[J]. Ann Surg Oncol, 2018, 25(9):2747-2755. DOI:10.1245/s10434-018-6648-6. [17] Wang S, Liao Z, Chen Y, et al. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation:a single-institution experience[J]. J Thorac Oncol, 2006, 1(3):252-259. DOI:10.1016/s1556-0864(15)31576-8. [18] Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy[J]. Radiother Oncol, 2015, 116(2):257-261. DOI:10.1016/j.radone.2015.07.011. [19] 赵丹, 郑宝敏, 肖绍文, 等. 颈段食管癌放疗患者复发模式及生存分析[J]. 中华放射医学与防护杂志, 2019, 39(1):44-50. DOI:10.3760/cma.j.issn.0254.5098.2019.01.009. Zhao D, Zheng BM, Xiao SW, et al. Patterns of failure and clinical outcomes of radiotherapy for cervical esophageal carcinoma[J]. Chin J Radiol Med Prot, 2019, 39(1):44-50. DOI:10.3760/cma.j.issn.0254.5098.2019.01.009. [20] Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma[J]. Radiat Oncol, 2013, 27(8):75-80. DOI:10.1186/1748-717X-8-75. [21] Du XX, Yu R, Wang ZF, et sl. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy[J]. Bosn J Basic Med Sci, 2019, 19(2):186-194. DOI:10.17305/bjbms.2019.3873. [22] Cao CN, Luo JW, Gao L, et al. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma:clinical outcomes and patterns of failure[J]. Eur Arch Otorhinolaryngol, 2016, 273(3):741-747. DOI:10.1007/s00405-015-3576-y. [23] Li M, Zhang X, Zhao F, et al. Involved-field radiotherapy for esophageal squamous cell carcinoma:theory and practice[J]. Radiat Oncol, 2016, 5(11):18-26. DOI:10.1186/s13014-016-0589-7. [24] Zhao L, Zhou Y, Mu Y, et al. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer[J]. Oncotarget, 2017, 8(13):21852-21860. DOI:10.18632/oncotarget.15665. [25] Yamashita H, Okuma K, Wakui R, et al. Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma-a retrospective analysis[J]. Radiother Oncol, 2011, 98(2):255-260. DOI:10.1016/j.radonc.2010.10.021. [26] Onozawa M, Nihei K, Ishikura S, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus[J]. Radiother Oncol, 2009, 92(2):266-269. DOI:10.1016/j.radonc.2008.09.025. [27] Jing W, Zhu H, Guo HB, et al. Correction:feasibility of elective nodal irradiation (ENI) and involved field irradiation (IFI) in radiotherapy for the elderiy patients (aged≥70 years) with esophageal squamous cell cancer:a retrospective analysis from a single institute[J]. PLoS One, 2016, 11(1):e0147453. DOI:10.1371/journal.pone.0147453. [28] Yamashita H, Takenaka R, Omori M, et al. Involved-field radiotherapy (IFRT) versus elective nodal irriation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers:a single instutional retrospective study[J]. Radiother Oncol, 2015, 10(2):171-180. DOI:10.1186/s13014-015-0482-9. [29] Sun Y, Zhang XL, Mao QF, et al. Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer:a retrospective analysis in clinical N0 patients[J]. Curr Oncol, 2018, 25(5):e423-e429. DOI:10.3747/co.25.3895. [30] Li Q, Zhu S, Li S, et al. Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation[J]. Medicine (Baltimore), 2019, 98(3):e14080. DOI:10.1097/MD.0000000000014080.
2020, Vol. 29 
